Insilico Medicine has entered a global drug discovery collaboration with Eli Lilly and Company that could be worth approximately $2.75B. The partnership will use Insilico’s AI engine to accelerate the discovery and development of novel therapeutics across multiple therapeutic areas.
Under the agreement, Lilly receives an exclusive worldwide license for the development, manufacturing, and commercialization of potentially best-in-class, novel oral therapeutics in preclinical development for certain indications. The companies will also collaborate on multiple R&D programs focused on targets selected by Lilly, combining Insilico’s Pharma.AI platforms with Lilly’s development capabilities and disease-area expertise.
“From its inception, Insilico Medicine has been developing deep learning for end-to-end drug discovery,” said Alex Zhavoronkov, PhD, founder and CEO of Insilico Medicine. He said the company’s frontier AI technologies, which scale from biomarkers to “world models of human and animal life,” can identify multi-purpose targets driving multiple diseases at the same time, and that working with Lilly aims to deliver transformative therapies for diseases with high unmet need.
Insilico is eligible to receive a $115 million upfront payment, with additional development, regulatory, and commercial milestones potentially bringing the total deal value to about $2.75 billion, plus tiered royalties on future sales. Andrew Adams, Group Vice President of Molecule Discovery at Lilly, said Insilico’s AI-enabled discovery capabilities are a powerful complement to Lilly’s clinical development expertise and that the collaboration will allow both parties to explore novel mechanisms and accelerate identification of promising therapeutic candidates across multiple disease areas.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!